Biosimilar Development News

  1. Stada And Xbrane Obtain British Approval For Ximluci (Ranibizumab) Biosimilar Referencing Lucentis 1/16/2023

    STADA Arzneimittel AG and Xbrane Biopharma AB announce that the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has granted a marketing authorization for Ximluci (ranibizumab), a biosimilar referencing Lucentis.

  2. Adalimumab, Infliximab And Etanercept Biosimilars Global Market Report 2023: Sector To Reach $5.59B By 2026 At A 15.2% CAGR 1/16/2023

    The "Adalimumab, Infliximab And Etanercept Biosimilars Global Market Opportunities And Strategies To 2031" report has been added to  ResearchAndMarkets.com's offering.

  3. Alvotech And Fuji Pharma Expand Partnership Adding A New Biosimilar Candidate 1/13/2023

    Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, and Japanese pharmaceutical company Fuji Pharma Co., Ltd.

  4. Biosimilar Contract Manufacturing Global Market Report 2022: Favorable Policies Encouraging Use Of Biosimilars Present Opportunities 1/12/2023

    The "Biosimilar Contract Manufacturing Market - Global Outlook & Forecast 2022-2027" report has been added to ResearchAndMarkets.com's offering.

  5. The Global Biosimilar Contract Manufacturing Market Is Expected To Grow At A CAGR Of 16.19% During 2022-2027 1/12/2023

    Biologic drugs are at the forefront of therapeutic developments, but their high cost accounts for a significant portion of public and private drug expenditure.

  6. Alvotech Initiates Pharmacokinetic Study For AVT05, A Proposed Biosimilar For Simponi® And Simponi Aria 1/11/2023

    Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today the initiation of a pharmacokinetic study for AVT05, a biosimilar candidate to Simponi® and Simponi Aria® (golimumab). The study will assess the pharmacokinetics, safety, and tolerability of AVT05 compared to Simponi® in healthy adult subjects.

  7. Implications Of Biosimilar Availability In The United States' Ophthalmology Markets Highlighted In New Spherix Global Insights Study 1/10/2023

    Ophthalmologists saw the entry of the first biosimilars into the armamentarium in 2022 with the launch of Biogen and Samsung's Byooviz and Coherus Bioscience's Cimerli (both biosimilars to Genentech's Lucentis). But are they being used?

  8. Bioprocess Validation Market Worth $842.5M By 2030: Grand View Research, Inc. 1/10/2023

    The global bioprocess validation market size is projected to reach USD 842.5 million by 2030, at a CAGR of 9.10% from 2023 to 2030, according to a new report by Grand View Research, Inc. Bioprocess validation is the process of documentation of all the stages, activities and procedures of the bioproduct formation.

  9. Celltrion And Rani Therapeutics Partner On Development Of Oral Monoclonal Antibody Treatment 1/9/2023

    Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced that it has partnered with Celltrion for the development of RT-111, an orally administered ustekinumab biosimilar.

  10. Coherus Agrees To Acquire Exclusive U.S. Commercial Rights To Eylea® Biosimilar FYB203 From Klinge Biopharma 1/9/2023

    Coherus BioSciences, Inc. (Coherus or Coherus BioSciences, Nasdaq: CHRS) announced today that it has executed a binding term sheet with Klinge Biopharma GmbH (Klinge Biopharma) for the exclusive commercialization rights to FYB203, a biosimilar candidate to Eylea® (aflibercept), in the United States.